Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A*0201 context

Patent metadata

Field	Value
Publication number	US-12227590-B2
Application number	US-202117552862-A
Country	US
Kind code	B2
Filing date	Dec 16, 2021
Priority date	Jun 21, 2019
Publication date	Feb 18, 2025
Grant date	Feb 18, 2025

Abstract

Disclosed are Synovial Sarcoma X breakpoint 2 binding molecules and methods for their use in the detection and treatment of cancer.

First claim

What is claimed is:

1. A Synovial Sarcoma X breakpoint 2 (SSX2) binding molecule comprising:
(i) 3 complementarity determining regions (CDRs) from the light chain variable region, wherein
the first CDR comprises the sequence set forth in SEQ ID NO: 1,
the second CDR comprises the sequence set forth in SEQ ID NO: 2, and
the third CDR comprises the sequence set forth in SEQ ID NO: 3; and

(ii) 3 CDRs from the heavy chain variable region, wherein
the first CDR comprises the sequence set forth in SEQ ID NO: 4,
the second CDR comprises the sequence set forth in SEQ ID NO: 5, and
the third CDR comprises the sequence set forth in SEQ ID NO: 6;

wherein the binding molecule targets a SSX2 peptide 41-49 (SEQ ID NO:07).

2. The SSX2 binding molecule of claim 1 , wherein the binding molecule targets the SSX2 peptide 41-49 (SEQ ID NO: 7) in the context of human leukocyte antigen (HLA)-A*0201.

3. The SSX2 binding molecule of claim 1 , wherein the binding molecule is an antibody, diabody, triabody, antigen binding fragment, bi-specific killer engager (BIKE), or tri-specific killer engager (TriKE).

4. The SSX2 binding molecule of claim 3 , wherein the antibody is of IgG1, IgG2, IgG3, IgG4, IgM or IgA isotype.

5. A chimeric antigen receptor (CAR) comprising the Synovial Sarcoma X breakpoint 2 (SSX2) binding molecule of claim 1 .

6. The CAR of claim 5 , further comprising one or more activating intra-cellular domains derived from CD3zeta, CD28, 4-1BB, OX40L or 2B4.

7. A cell comprising the CAR of claim 5 , wherein the cell is a T cell or NK cell.

Assignees

• Tschiersch Pfrelindschuh Astrid
• Childrens Nat Medical Ct
• Univ George Washington
• Univ Saarland

Inventors

• Yvon Eric
• Bollard Catherine
• Van Pelt Stacey
• Raskin Scott
• Held Gerhard
• Sturm Christine
• Pfreundschuh Deseased Michael

Classifications

• A61K40/4267

  Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/48

  Blood cells, e.g. leukemia or lymphoma · CPC title

• C07K2319/33

  fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title